Published in Eur J Clin Pharmacol on June 01, 2000
Methylene blue and serotonin toxicity: inhibition of monoamine oxidase A (MAO A) confirms a theoretical prediction. Br J Pharmacol (2007) 1.81
Effects of post-session administration of methylene blue on fear extinction and contextual memory in adults with claustrophobia. Am J Psychiatry (2014) 1.48
Methylene blue reduces aβ levels and rescues early cognitive deficit by increasing proteasome activity. Brain Pathol (2011) 1.46
In vitro assessment of methylene blue on chloroquine-sensitive and -resistant Plasmodium falciparum strains reveals synergistic action with artemisinins. Antimicrob Agents Chemother (2005) 1.46
Neurometabolic mechanisms for memory enhancement and neuroprotection of methylene blue. Prog Neurobiol (2011) 1.37
Real-time, near-infrared, fluorescence-guided identification of the ureters using methylene blue. Surgery (2010) 1.29
High absolute bioavailability of methylene blue given as an aqueous oral formulation. Eur J Clin Pharmacol (2008) 1.27
Cellular and molecular actions of Methylene Blue in the nervous system. Med Res Rev (2011) 1.22
Aromatic small molecules remodel toxic soluble oligomers of amyloid beta through three independent pathways. J Biol Chem (2010) 1.20
Pharmacokinetic interaction of chloroquine and methylene blue combination against malaria. Eur J Clin Pharmacol (2004) 1.19
Clinical outcomes and kinetics of propanil following acute self-poisoning: a prospective case series. BMC Clin Pharmacol (2009) 1.18
Extinction memory improvement by the metabolic enhancer methylene blue. Learn Mem (2004) 1.14
Methylene blue as a cerebral metabolic and hemodynamic enhancer. PLoS One (2012) 1.12
Methylene blue potentiates stimulus-evoked fMRI responses and cerebral oxygen consumption during normoxia and hypoxia. Neuroimage (2013) 1.08
Neuroprotective efficacy of methylene blue in ischemic stroke: an MRI study. PLoS One (2013) 1.07
Fiberoptic endoscopic evaluation of swallowing (FEES) with and without blue-dyed food. Dysphagia (2005) 1.04
Pharmacologic agents for acute hemodynamic instability: Recent advances in the management of perioperative shock- A systematic review. Ann Card Anaesth (2015) 1.01
The brain metabolic enhancer methylene blue improves discrimination learning in rats. Pharmacol Biochem Behav (2007) 1.01
Pharmacological enhancement of fear reduction: preclinical models. Br J Pharmacol (2011) 0.99
Neuroprotective actions of methylene blue and its derivatives. PLoS One (2012) 0.99
Beneficial network effects of methylene blue in an amnestic model. Neuroimage (2010) 0.94
Methylene blue modulates huntingtin aggregation intermediates and is protective in Huntington's disease models. J Neurosci (2012) 0.92
Striatal neuroprotection with methylene blue. Neuroscience (2009) 0.90
Modulation of protein-protein interactions as a therapeutic strategy for the treatment of neurodegenerative tauopathies. Curr Top Med Chem (2011) 0.89
Influence of methylene blue on microglia-induced inflammation and motor neuron degeneration in the SOD1(G93A) model for ALS. PLoS One (2012) 0.89
Preventive methylene blue treatment preserves cognition in mice expressing full-length pro-aggregant human Tau. Acta Neuropathol Commun (2015) 0.87
The efficacy of arm node preserving surgery using axillary reverse mapping for preventing lymphedema in patients with breast cancer. J Breast Cancer (2012) 0.86
Methylene blue treatment delays progression of perfusion-diffusion mismatch to infarct in permanent ischemic stroke. Brain Res (2014) 0.86
Effect of methylene blue on the genomic response to reperfusion injury induced by cardiac arrest and cardiopulmonary resuscitation in porcine brain. BMC Med Genomics (2010) 0.85
Methylene blue attenuates traumatic brain injury-associated neuroinflammation and acute depressive-like behavior in mice. J Neurotrauma (2014) 0.85
Effect of a single bolus of methylene blue prophylaxis on vasopressor and transfusion requirement in infective endocarditis patients undergoing cardiac surgery. Korean J Anesthesiol (2012) 0.82
Photoacoustic lifetime contrast between methylene blue monomers and self-quenched dimers as a model for dual-labeled activatable probes. J Biomed Opt (2013) 0.82
A review on mitochondrial restorative mechanism of antioxidants in Alzheimer's disease and other neurological conditions. Front Pharmacol (2015) 0.82
Tau-Centric Targets and Drugs in Clinical Development for the Treatment of Alzheimer's Disease. Biomed Res Int (2016) 0.81
Effects of oxidized and reduced forms of methylthioninium in two transgenic mouse tauopathy models. Behav Pharmacol (2015) 0.81
Immediate and Long-Term Outcome of Acute H2S Intoxication Induced Coma in Unanesthetized Rats: Effects of Methylene Blue. PLoS One (2015) 0.81
The Effects of Methylene Blue on Autophagy and Apoptosis in MRI-Defined Normal Tissue, Ischemic Penumbra and Ischemic Core. PLoS One (2015) 0.80
Stroke neuroprotection: targeting mitochondria. Brain Sci (2013) 0.80
Quantitative assessment of nipple perfusion with near-infrared fluorescence imaging. Ann Plast Surg (2013) 0.80
Evaluation of the protein biomarkers and the analgesic response to systemic methylene blue in patients with refractory neuropathic pain: a double-blind, controlled study. J Pain Res (2015) 0.80
Therapeutic approaches to delay the onset of Alzheimer's disease. J Aging Res (2011) 0.79
Lack of effect of methylene blue in the SOD1 G93A mouse model of amyotrophic lateral sclerosis. PLoS One (2011) 0.78
Methylene blue modulates transendothelial migration of peripheral blood cells. PLoS One (2013) 0.78
Attenuation of noise-induced hearing loss using methylene blue. Cell Death Dis (2014) 0.77
Injectable Clostridium histolyticum collagenase as a potential treatment for uterine fibroids. Reprod Sci (2014) 0.77
Developing effective countermeasures against acute hydrogen sulfide intoxication: challenges and limitations. Ann N Y Acad Sci (2016) 0.76
Multimodal Randomized Functional MR Imaging of the Effects of Methylene Blue in the Human Brain. Radiology (2016) 0.76
Methylene blue modulates β-secretase, reverses cerebral amyloidosis, and improves cognition in transgenic mice. J Biol Chem (2014) 0.76
Alternative mitochondrial electron transfer for the treatment of neurodegenerative diseases and cancers: Methylene blue connects the dots. Prog Neurobiol (2015) 0.75
Green urine: A cause for concern? J Anaesthesiol Clin Pharmacol (2017) 0.75
Methylene blue treatment in experimental ischemic stroke: a mini review. Brain Circ (2016) 0.75
It's not easy being blue-green. Ann Lab Med (2013) 0.75
Methylene blue modulates functional connectivity in the human brain. Brain Imaging Behav (2016) 0.75
Antifungal Action of Methylene Blue Involves Mitochondrial Dysfunction and Disruption of Redox and Membrane Homeostasis in C. albicans. Open Microbiol J (2016) 0.75
The Interactions of P-Glycoprotein with Antimalarial Drugs, Including Substrate Affinity, Inhibition and Regulation. PLoS One (2016) 0.75
Methylene blue inhibits function of the 5-HT transporter. Br J Pharmacol (2012) 0.75
On-site ultrasound-guided localization for impalpable nodal recurrences in papillary thyroid carcinoma patients. J Korean Surg Soc (2013) 0.75
Surgeon-performed intraoperative tumor localization in recurrent papillary thyroid carcinoma by ultrasound-guided intratumoral indigo carmine injection. World J Surg (2014) 0.75
Methylene blue and its analogues as antidepressant compounds. Metab Brain Dis (2017) 0.75
Prophylactic treatment of known ifosfamide-induced encephalopathy for chemotherapy with high-dose ifosfamide? Support Care Cancer (2004) 0.75
Targeting mitochondrial dysfunction in CNS injury using Methylene Blue; still a magic bullet? Neurochem Int (2017) 0.75
P2X7 receptor as a novel drug delivery system to increase the entrance of hydrophilic drugs into cells during photodynamic therapy. J Bioenerg Biomembr (2016) 0.75
Development and Characterization of Methylene Blue Oleate Salt-Loaded Polymeric Nanoparticles and their Potential Application as a Treatment for Glioblastoma. J Nanomed Nanotechnol (2017) 0.75
Pharmacogenetics of mephenytoin: a new drug hydroxylation polymorphism in man. Eur J Clin Pharmacol (1984) 2.66
Polymorphic dextromethorphan metabolism: co-segregation of oxidative O-demethylation with debrisoquin hydroxylation. Clin Pharmacol Ther (1985) 2.50
False positives with current carbocisteine protocol for sulphoxidation phenotyping. Lancet (1990) 2.05
Compartmentation of glutathione: implications for the study of toxicity and disease. Toxicol Appl Pharmacol (1996) 2.00
Plasma glutathione and glutathione disulfide in the rat: regulation and response to oxidative stress. J Pharmacol Exp Ther (1983) 1.79
Effect of N-acetylcysteine on plasma cysteine and glutathione following paracetamol administration. Eur J Clin Pharmacol (1989) 1.50
Expiratory measurement of maximal amino-pyrine demethylation in vivo: effect of phenobarbital, partial hepatectomy, protacaval shunt and bile duct ligation in the rat. J Pharmacol Exp Ther (1976) 1.41
Aminopyrine demethylation measured by breath analysis in cirrhosis. Clin Pharmacol Ther (1976) 1.35
Mechanism of action of N-acetylcysteine in the protection against the hepatotoxicity of acetaminophen in rats in vivo. J Clin Invest (1983) 1.31
The systemic availability of oral glutathione. Eur J Clin Pharmacol (1992) 1.29
Dextromethorphan as a safe probe for debrisoquine hydroxylation polymorphism. Lancet (1984) 1.26
Mephenytoin hydroxylation deficiency: kinetics after repeated doses. Clin Pharmacol Ther (1984) 1.25
Hepatic glutathione homeostasis in the rat: efflux accounts for glutathione turnover. Hepatology (1984) 1.23
Biliary excretion of glutathione and glutathione disulfide in the rat. Regulation and response to oxidative stress. J Clin Invest (1984) 1.18
Inherited defects of hepatic drug metabolism. Semin Liver Dis (1983) 1.17
Kava hepatotoxicity. Ann Intern Med (2001) 1.13
Reduced antioxidative capacity in liver mitochondria from bile duct ligated rats. Hepatology (1995) 1.13
Stimulation of respiration by methylene blue in rat liver mitochondria. FEBS Lett (1997) 1.10
Glutathione depletion in HIV-infected patients: role of cysteine deficiency and effect of oral N-acetylcysteine. AIDS (1992) 1.10
Regulation of hepatic glutathione turnover in rats in vivo and evidence for kinetic homogeneity of the hepatic glutathione pool. J Clin Invest (1981) 1.07
Therapeutic doses of acetaminophen stimulate the turnover of cysteine and glutathione in man. J Hepatol (1987) 1.06
Altered bile acid metabolism in primary biliary cirrhosis. Dig Dis Sci (1981) 1.03
Stereochemistry of aromatic phenytoin hydroxylation in various drug hydroxylation phenotypes in humans. J Pharmacol Exp Ther (1987) 1.03
High-dose intravenous glutathione in man. Pharmacokinetics and effects on cyst(e)ine in plasma and urine. Eur J Clin Invest (1991) 1.01
The effects of age and glutathione depletion on hepatic glutathione turnover in vivo determined by acetaminophen probe analysis. J Pharmacol Exp Ther (1980) 1.00
Pharmacogenetics of dextromethorphan O-demethylation in man. Xenobiotica (1986) 1.00
Stereoselective metabolism of mephenytoin in man. J Pharmacol Exp Ther (1981) 1.00
[Drug hydroxylation disorders (debrisoquin type) in a random sample of the Swiss population]. Schweiz Med Wochenschr (1982) 0.99
Inhibition of (mono)amine oxidase activity and prevention of ifosfamide encephalopathy by methylene blue. Drug Metab Dispos (1996) 0.97
Ethanol suppresses hepatic glutathione synthesis in rats in vivo. J Pharmacol Exp Ther (1984) 0.96
Clinical value of the bile acid breath test. Evaluation of the Mayo Clinic experience. Mayo Clin Proc (1978) 0.96
Stereoselective metabolism and disposition of the enantiomers of mephenytoin during chronic oral administration of the racemic drug in man. J Pharmacol Exp Ther (1982) 0.94
Ifosfamide by continuous infusion to prevent encephalopathy. Lancet (1990) 0.94
Stereoselective mephobarbital hydroxylation cosegregates with mephenytoin hydroxylation. Clin Pharmacol Ther (1985) 0.93
Hepatic functional deterioration after portacaval shunt in the rat. Effects on sulfobromophthalein transport-maximum, indocyanine green clearance and galactose elimination capacity. Gastroenterology (1976) 0.93
Decreased production of glutathione in patients with cirrhosis. Eur J Clin Invest (1987) 0.92
Quantitative liver function in patients with rheumatoid arthritis treated with low-dose methotrexate: a longitudinal study. Br J Rheumatol (1997) 0.92
Decreased release of glutathione into the systemic circulation of patients with HIV infection. Eur J Clin Invest (1996) 0.92
Toxic doses of acetaminophen suppress hepatic glutathione synthesis in rats. Hepatology (1982) 0.91
Thalidomide-induced peripheral neuropathy. A prospective clinical, neurophysiological and pharmacogenetic evaluation. J Neurol (1986) 0.90
Glutathione metabolism in activated human neutrophils: stimulation of glutathione synthesis and consumption of glutathione by reactive oxygen species. Eur J Clin Invest (1991) 0.90
Oxidant stress and hepatic necrosis in rats treated with diquat. J Pharmacol Exp Ther (1985) 0.90
Pharmacokinetics of the toxic hydrazino metabolites formed from isoniazid in humans. J Pharmacol Exp Ther (1985) 0.90
Divergent effects of intravenous GSH and cysteine on renal and hepatic GSH. Am J Physiol (1992) 0.89
Reperfusion injury of the liver: role of mitochondria and protection by glutathione ester. J Surg Res (1999) 0.89
Oxidation of mitochondrial proteins and DNA following administration of ethanol. Biochem Biophys Res Commun (1995) 0.88
Comparative pharmacokinetics of oral and intravenous ifosfamide/mesna/methylene blue therapy. Drug Metab Dispos (1998) 0.87
Effects of hypochlorous acid and chloramines on vascular resistance, cell integrity, and biliary glutathione disulfide in the perfused rat liver: modulation by glutathione. J Hepatol (1991) 0.87
Oxidation of hydrazine metabolites formed from isoniazid. Clin Pharmacol Ther (1985) 0.86
Inhibition and stimulation of long-chain fatty acid oxidation by chloroacetaldehyde and methylene blue in rats. J Pharmacol Exp Ther (1999) 0.85
Liver injury due to verapamil. Hepatogastroenterology (1988) 0.85
Oxidant stress during reperfusion of ischemic liver: no evidence for a role of xanthine oxidase. Hepatology (1988) 0.85
L-2-oxothiazolidine-4-carboxylic acid, a cysteine prodrug: pharmacokinetics and effects on thiols in plasma and lymphocytes in human. J Pharmacol Exp Ther (1991) 0.84
Breath test with isotopes of carbon: progress and potential. J Lab Clin Med (1977) 0.84
Prednisolone stimulates hepatic glutathione synthesis in mice. Protection by prednisolone against acetaminophen hepatotoxicity in vivo. J Hepatol (1993) 0.84
Time course of total cysteine, glutathione and homocysteine in plasma of patients with chronic hepatitis C treated with interferon-alpha with and without supplementation with N-acetylcysteine. J Hepatol (1998) 0.83
Quantitative liver function in the elderly assessed by galactose elimination capacity, aminopyrine demethylation and caffeine clearance. J Hepatol (1986) 0.83
Thiodiglycolic acid is excreted by humans receiving ifosfamide and inhibits mitochondrial function in rats. Drug Metab Dispos (1998) 0.83
Fish oil protects mice against acetaminophen hepatotoxicity in vivo. Hepatology (1991) 0.83
Saturable metabolism of continuous high-dose ifosfamide with mesna and GM-CSF: a pharmacokinetic study in advanced sarcoma patients. Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol (1999) 0.83
Increased urinary losses of carnitine during ifosfamide chemotherapy. Cancer Chemother Pharmacol (1999) 0.83
Continuous 5-day infusion of ifosfamide with mesna in inoperable pancreatic cancer patients: a phase II study. J Cancer Res Clin Oncol (1991) 0.82
Analysis of hydroxylated and demethylated metabolites of mephenytoin in man and laboratory animals using gas-liquid chromatography and high-performance liquid chromatography. J Chromatogr (1982) 0.82
Polymorphic acetylation and aminopyrine demethylation in Gilbert's syndrome. Eur J Clin Invest (1978) 0.82
Disposition of glutathione monoethyl ester in the rat: glutathione ester is a slow release form of extracellular glutathione. J Pharmacol Exp Ther (1995) 0.82
The differential localization of various drug metabolizing systems within the rat liver lobule as determined by the hepatotoxins allyl alcohol, carbon tetrachloride and bromobenzene. J Pharmacol Exp Ther (1981) 0.82
A major pathway of mephenytoin metabolism in man. Aromatic hydroxylation to p-hydroxymephenytoin. Drug Metab Dispos (1980) 0.81
Amitriptyline pharmacokinetics and clinical response: II. Metabolic polymorphism assessed by hydroxylation of debrisoquine and mephenytoin. Int Clin Psychopharmacol (1986) 0.81
The enigma of ifosfamide encephalopathy. Ann Oncol (1992) 0.81
Stereoselective metabolism and pharmacogenetic control of 5-phenyl-5-ethylhydantoin (nirvanol) in humans. J Pharmacol Exp Ther (1984) 0.81
Decreased glutathione in patients with anorexia nervosa. Risk factor for toxic liver injury? Eur J Clin Nutr (2004) 0.80
Plasmaperfusion for the treatment of intractable pruritus of cholestasis. Mayo Clin Proc (1978) 0.80
Chemical nature of reactive intermediates as determinant of toxicologic responses. Drug Metab Rev (1982) 0.80
Metabolism and pharmacokinetics of oral and intravenous ifosfamide. J Cancer Res Clin Oncol (1991) 0.80
Treatment of pruritus of cholestasis by plasma perfusion through USP-charcoal-coated glass beads. Lancet (1980) 0.80
Postischemic ATP levels predict hepatic function 24 hours following ischemia in the rat. Experientia (1988) 0.80
Cellular immunity in healthy volunteers treated with an octavalent conjugate Pseudomonas aeruginosa vaccine. Clin Exp Immunol (2006) 0.79
Supplementation of N-acetylcysteine fails to increase glutathione in lymphocytes and plasma of patients with AIDS. AIDS Res Hum Retroviruses (1995) 0.79
Assessment of mitochondrial function in vivo with a breath test utilizing alpha-ketoisocaproic acid. Hepatology (1989) 0.79
Acetylation of acetylhydrazine, the toxic metabolite of isoniazid, in humans. Inhibition by concomitant administration of isoniazid. J Pharmacol Exp Ther (1987) 0.79
Increased urinary excretion of toxic hydrazino metabolites of isoniazid by slow acetylators. Effect of a slow-release preparation of isoniazid. Eur J Clin Pharmacol (1987) 0.79
Bioavailability of subcutaneous ifosfamide and feasibility of continuous outpatient application in cancer patients. Ann Oncol (1990) 0.79
Induction of drug-metabolizing enzymes by the enantiomers of normephenytoin in the rat. Drug Metab Dispos (1981) 0.79
[Urinary bioavailability of sodium-2-mercaptoethanesulfonate (Uromitexan) following intravenous, subcutaneous and continuous subcutaneous administration]. Schweiz Med Wochenschr (1989) 0.78
Effect of allopurinol on oxidant stress and hepatic function following ischemia and reperfusion in the rat. Liver (1988) 0.78
Depletion of total cysteine, glutathione, and homocysteine in plasma by ifosfamide/mesna therapy. Cancer Chemother Pharmacol (1994) 0.78
Oral bioavailability of mesna tablets. Cancer Chemother Pharmacol (1993) 0.78
Endotoxin causes neutrophil-independent oxidative stress in rats. J Appl Physiol (1985) (1988) 0.78
Phenytoin therapy for epileptic children: evaluation of salivary and plasma concentrations and of methods of assessing compliance. Dev Med Child Neurol (1981) 0.78
Enantioselectivity of 4-hydroxylation in extensive and poor metabolizers of debrisoquine. Br J Clin Pharmacol (1988) 0.78
Defective bile acid transport in an animal model of defective debrisoquine hydroxylation. Biochem Pharmacol (1986) 0.77
Ethanol decreases plasma sulphydryls in man: effect of disulfiram. Eur J Clin Invest (1988) 0.77
Hepatic metabolism of aminopyrine in patients with chronic renal failure. Clin Sci Mol Med (1978) 0.77
Methylene blue and fatal encephalopathy from ackee fruit poisoning. Lancet (1999) 0.77
Plasma glutathione disulfide as an index of oxidant stress in vivo: effects of carbon tetrachloride, dimethylnitrosamine, nitrofurantoin, metronidazole, doxorubicin and diquat. Res Commun Chem Pathol Pharmacol (1984) 0.77
Pharmacokinetics of 2-chloro-2'-deoxyadenosine administered subcutaneously or by continuous intravenous infusion. Cancer Chemother Pharmacol (2000) 0.77
Solvent isotope effect on bile formation in the rat. Biochem J (1995) 0.77
Mitochondrial function reflected by the decarboxylation of [13C]ketoisocaproate is impaired in alcoholics. Alcohol Clin Exp Res (1994) 0.77